UPDATE ON INVESTMENT
22/07/2024 07:00
For best results when printing this announcement, please click on link below: http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240722:nRSV1856Xa&default-theme=true RNS Number : 1856X BioPharma Credit PLC 22 July 2024 22 July 2024 BIOPHARMA CREDIT PLC UPDATE ON INVESTMENT BioPharma Credit PLC (LSE: BPCR) notes the update on the UK CMA (Competition and Markets Authority) website made on 19 July 2024 regarding the CMA's clearance of the proposed acquisition of LumiraDx by Roche. The updated website can be found in its entirety at: UK CMA Roche / LumiraDx merger inquiry. (https://www.gov.uk/cma-cases/roche-slash-lumiradx-merger-inquiry) With the CMA's clearance of the acquisition, we understand from LumiraDx that they are working with Roche towards finalizing the acquisition closing. We await further confirmation as to the status of the transaction and the satisfaction of all conditions to acquisition closing, including regulatory and antitrust review. At this time, Pharmakon Advisors, LP cannot further comment beyond what has been made public by the CMA and the companies involved in the transaction. Pharmakon Advisors, LP is continuing to actively monitor the situation and will provide any updates in due course. Enquiries Buchanan David Rydell / Mark Court / Jamie Hooper / Henry Wilson +44 (0) 20 7466 5000 biopharmacredit@buchanan.uk.com (mailto:biopharmacredit@buchanan.uk.com) Notes to Editors BioPharma Credit PLC is London's only specialist debt investor to the life sciences industry and joined the LSE in March 2017. BioPharma Credit PLC seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. BioPharma Credit PLC seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com (mailto:rns@lseg.com) or visit www.rns.com (http://www.rns.com/) . RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy) . END UPDRBMLTMTTTBLI